Impact Factor 4.599 | CiteScore 3.7
More on impact ›
Cancer Genetics welcomes manuscripts contributing to the understanding of the impact of genetic aberrations in carcinogenesis, as well as in the progression and outcomes of cancer. (Basic, translational and clinical research is welcome, with genetic, genomic and transcriptomic studies being considered for the section).
Manuscripts consisting solely of bioinformatic research, as well as focused on proteomic and metabolomic investigation, are regrettably not suitable for this specialty.
The acquisition of somatic genetic aberrations is central to the development of cancer, along with the constitutional genetic background of each patient in their cancer risk and response to therapy. Current technologies provide ever more powerful approaches to study and validate these highly complex phenomena. The Cancer Genetics specialty section will facilitate the publication of high-quality original research and review articles pertaining to the genetic, genomic and molecular aspects of cancer, and technical advances that facilitate progress in this field.
Focused primarily on molecular genetic aberrations driving malignant processes in human cancers, the scope of submissions will include investigations in the following areas:
Submissions not in scope for this specialty include:
Indexed in: PubMed, PubMed Central (PMC), Scopus, Google Scholar, DOAJ, CrossRef, Chemical Abstracts Service (CAS), Embase, AGRICOLA, Semantic Scholar, Ulrich's Periodicals Directory, BIOSIS Citation Index, Biological Abstracts, CLOCKSS, EBSCO, OpenAIRE, Zetoc, Mastermind
PMCID: all published articles receive a PMCID
Avenue du Tribunal Fédéral 34
CH – 1005 Lausanne
Tel +41(0)21 510 17 40
Fax +41 (0)21 510 17 01
For all queries regarding manuscripts in Review and potential conflicts of interest, please contact firstname.lastname@example.org
For queries regarding Research Topics, Editorial Board applications, and journal development, please contact email@example.com